Betty Herrington
Pediatric Hematology-Oncology · Jackson, MSNPI 1437363967
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $16,470 of the $22,913 with a category attached, or 71.9%. Day One Biopharmaceuticals accounts for 95.9% of it on its own, with 22 other manufacturers making up the rest. 2025 is the largest year on record at $15,680, more than ten times the $237 reported in 2019.
Across 70 payments — averaging $327.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Day One Biopharmaceuticals$22K
- CSL Behring$91
- Novo Nordisk$80
- Merck$78
- Servier Pharmaceuticals LLC$73
- Springworks Therapeutics, Inc.$68
- plus $558 from 17 others
Across 28 payments — averaging $6804.19 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$105K
- Jazz Pharmaceuticals Inc.$36K
- E.r. Squibb & Sons, L.L.C.$30K
- Pfizer$12K
- Daiichi Sankyo Inc.$7K
What the payments were for
- Consulting fees$1,8758%
- Speaking & faculty fees$16,47072%
- Travel & lodging$3,23114%
- Food & beverage$1,3376%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Day One Biopharmaceuticals | 22 | $21,966 |
| CSL Behring | 4 | $91 |
| Novo Nordisk | 4 | $80 |
| Merck | 4 | $78 |
| Servier Pharmaceuticals LLC | 6 | $73 |
| Springworks Therapeutics, Inc. | 3 | $68 |
| Novartis | 2 | $66 |
| AstraZeneca | 3 | $61 |
| Pfizer | 2 | $56 |
| Jazz Pharmaceuticals Inc. | 3 | $55 |
| Amgen | 3 | $47 |
| Adaptive Biotechnologies Corporation | 1 | $35 |
| Global Blood Therapeutics, Inc. | 2 | $31 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $29 |
| Teleflex LLC | 1 | $26 |
| RARE Disease Therapeutics, Inc. | 1 | $24 |
| Mesoblast, Inc. | 1 | $23 |
| Bristol Myers Squibb | 1 | $21 |
| Sanofi-aventis U.S. LLC | 1 | $19 |
| Emmaus Medical, Inc. | 1 | $17 |
| ADMA Biomanufacturing LLC | 1 | $17 |
| Grifols USA, LLC | 1 | $15 |
| Sobi, Inc | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- OJEMDA$21,817
How this compares
Too few pediatric hematology-oncology providers in Mississippito place this figure against a meaningful peer group, so we don't.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AfinitorEverolimus | 14 | $256,132 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisAfinitor | $66 | $256,13214 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few pediatric hematology-oncology providers in Mississippion file to place this against a meaningful peer group, so we don't.
Other pediatric hematology-oncology in Jackson
- Laura ArnoldJackson$2K
- Anderson CollierJackson$2K
- Catherine GordonJackson$1K
- Amanda StrobelJackson$731
- Melissa McNaullJackson$388
- Rathi IyerJackson$61
- Spencer SullivanMadison$92K
- Sharon PenningtonFlowood$17K
- Mauricio Rendon BernotPicayune$47
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.